Marleen De Vriese and Hans Platteeuw are attending this weeks’ biannual meeting on Buruli Ulcer and Skin NTD’s at the WHO headquarters in Geneva (Switzerland).
We are present to show and obtain feedback on a novel oral once daily Fixed Dose Combination Tablet which contains rifampicin and clarithromycin that could facilitate the treatment of Buruli Ulcer in endemic countries, especially in combination with a proper and timely diagnosis and advanced wound care.
